Aptose Biosciences (NASDAQ:APTO) Announces Earnings Results

Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03, MarketWatch Earnings reports. During the same period in the prior year, the firm earned ($0.18) EPS.

Shares of NASDAQ APTO opened at $1.12 on Tuesday. Aptose Biosciences has a fifty-two week low of $1.00 and a fifty-two week high of $5.78. The firm has a market capitalization of $103.29 million, a P/E ratio of -1.53 and a beta of 1.50. The company’s 50 day simple moving average is $1.21 and its 200 day simple moving average is $1.52.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in shares of Aptose Biosciences during the 4th quarter valued at $31,000. Millennium Management LLC lifted its stake in Aptose Biosciences by 57.6% in the fourth quarter. Millennium Management LLC now owns 1,091,222 shares of the biotechnology company’s stock valued at $1,474,000 after buying an additional 398,691 shares during the period. Cubist Systematic Strategies LLC acquired a new position in Aptose Biosciences in the fourth quarter valued at about $92,000. D. E. Shaw & Co. Inc. bought a new position in Aptose Biosciences during the fourth quarter worth about $357,000. Finally, Renaissance Technologies LLC grew its position in shares of Aptose Biosciences by 30.4% during the 4th quarter. Renaissance Technologies LLC now owns 942,625 shares of the biotechnology company’s stock worth $1,273,000 after buying an additional 219,620 shares during the period. 34.21% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts recently weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Aptose Biosciences in a report on Friday, April 1st. StockNews.com began coverage on Aptose Biosciences in a research report on Thursday, March 31st. They issued a “sell” rating on the stock. Finally, HC Wainwright restated a “buy” rating on shares of Aptose Biosciences in a research report on Wednesday, March 23rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Aptose Biosciences has an average rating of “Buy” and a consensus price target of $7.50.

About Aptose Biosciences (Get Rating)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

See Also